Cell Therapy Products in Alzheimer Disease

Area of Science:

• Neuroscience
• Gerontology
• Endocrinology

Background:

• Societal aging increases the prevalence of age-related cognitive decline, a significant public health concern.
• Estrogen's impact on the brain is increasingly recognized, with declining levels during menopause potentially influencing Alzheimer's disease risk.
• A novel hypothesis posits Alzheimer's disease as a form of postmenopausal dementia resulting from estrogen deficiency.

Purpose of the Study:

• To review the causes of postmenopausal Alzheimer's disease.
• To explore emerging cell therapies for postmenopausal Alzheimer's disease.

Main Methods:

• Literature review on the relationship between estrogen, menopause, and Alzheimer's disease.
• Investigation of cell-based therapeutic strategies currently under development.

Main Results:

• Alzheimer's disease is hypothesized to be a consequence of estrogen deficiency in postmenopausal women.
• Two promising cell therapies are under investigation: one inhibiting amyloid beta formation, and another utilizing umbilical cord blood-derived mesenchymal stem cells.

Conclusions:

• Estrogen deficiency following menopause is a key factor in Alzheimer's disease development.
• Cell therapies offer potential new avenues for treating postmenopausal Alzheimer's disease.